PMID- 26897036
OWN - NLM
STAT- MEDLINE
DCOM- 20161020
LR  - 20181113
IS  - 1477-7819 (Electronic)
IS  - 1477-7819 (Linking)
VI  - 14
IP  - 1
DP  - 2016 Feb 20
TI  - Prognostic role of HER2 amplification based on fluorescence in situ hybridization 
      (FISH) in pancreatic ductal adenocarcinoma (PDAC): a meta-analysis.
PG  - 38
LID - 10.1186/s12957-016-0792-x [doi]
LID - 38
AB  - BACKGROUND: Previous studies have shown that human epidermal growth factor 
      receptor 2 (HER2) may play an important role in the invasion and metastasis of 
      pancreatic cancer, but the relationship between HER2 amplification level and 
      prognosis of pancreatic cancer patients is still controversial. Therefore, we 
      performed a meta-analysis to determine the prognostic significance of HER2 
      amplification based on fluorescence in situ hybridization (FISH) in patients with 
      pancreatic cancer. METHODS: PubMed, EMBASE, and Web of Science (Jan 2001 to Jun 
      2015) were searched. Only articles that detect the HER2 amplification by FISH 
      method were included. RevMan 5.3 and STATA version 12 were used to perform this 
      meta-analysis. Pooled calculations were carried out on hazard ratio (HR) and 95% 
      confidence interval (CI) to assess the risk of disease. RESULTS: A total of six 
      eligible studies were enrolled in meta-analysis. The univariate analysis results 
      showed that HER2 amplification was not significantly associated with patients' 
      overall survival (pooled HR, 1.87, 95% CI, 0.64-5.46, P=0.25), which are 
      maintained in one study of multivariate analysis (HR 0.51, 95% CI, 0.12-2.14, 
      P=0.358). HER2 amplification also had no correlation with clinicopathological 
      factors such as age, gender, lymph node metastasis, and tumor stage. CONCLUSIONS: 
      Our results showed that HER2 amplification based on FISH may not be a good 
      prognostic factor for survival in patients with pancreatic cancer.
FAU - Li, Xiaoping
AU  - Li X
AD  - Department of Oncology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong 
      University, Shanghai, 200092, China. lxpyahoo@hotmail.com.
FAU - Zhao, Hua
AU  - Zhao H
AD  - Department of Oncology, Baoshan People Hospital, Yunnan, 678000, China.
FAU - Gu, Jianchun
AU  - Gu J
AD  - Department of Oncology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong 
      University, Shanghai, 200092, China.
FAU - Zheng, Leizhen
AU  - Zheng L
AD  - Department of Oncology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong 
      University, Shanghai, 200092, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20160220
PL  - England
TA  - World J Surg Oncol
JT  - World journal of surgical oncology
JID - 101170544
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/*genetics
MH  - Carcinoma, Pancreatic Ductal/*genetics/secondary
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lymphatic Metastasis
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Pancreatic Neoplasms/*genetics/pathology
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics
MH  - Survival Rate
PMC - PMC4761213
EDAT- 2016/02/22 06:00
MHDA- 2016/10/21 06:00
PMCR- 2016/02/20
CRDT- 2016/02/22 06:00
PHST- 2015/12/09 00:00 [received]
PHST- 2016/02/16 00:00 [accepted]
PHST- 2016/02/22 06:00 [entrez]
PHST- 2016/02/22 06:00 [pubmed]
PHST- 2016/10/21 06:00 [medline]
PHST- 2016/02/20 00:00 [pmc-release]
AID - 10.1186/s12957-016-0792-x [pii]
AID - 792 [pii]
AID - 10.1186/s12957-016-0792-x [doi]
PST - epublish
SO  - World J Surg Oncol. 2016 Feb 20;14(1):38. doi: 10.1186/s12957-016-0792-x.